- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Amneal buys Actavis’ Australian generics business
Amneal Pharmaceuticals has completed its acquisition of Actavis’ Australian-based generic pharmaceuticals business. Financial terms of the deal were not disclosed.
Amneal Pharmaceuticals has completed its acquisition of Actavis’ Australian-based generic pharmaceuticals business. Financial terms of the deal were not disclosed.
Related: Actavis gains final FDA approval for generic Subutex
Both companies vowed to work expeditiously to complete the transaction without disrupting the distribution of Actavis’ products. Click here to read the announcement.
The agreement grants Amneal, based in Switzerland, the right to distribute Actavis-labeled products on a transitional basis.
Ireland-based Actavis completed a buyout of Botox-maker Allergan Inc. for $66 billion earlier this month. After it gains shareholder approval, Actavis will adopt the Allergan name.
